Indivior PLC
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Indivior PLC Indivior plc (NASDAQ:INDV) develops, manufactures, and markets buprenorphine-based prescription drugs for the treatment of opioid use disorder and co-occurring disorders worldwide; its core products include SUBLOCADE (buprenorphine extended-release monthly injection), SUBOXONE (buprenorphine/naloxone sublingual film and tablet), SUBUTEX (buprenorphine sublingual tablet), OPVEE (nalmefene nasal spray for opioid overdose reversal), and OPNT003 (investigational opioid overdose treatment); the company also advances a pipeline addressing substance use disorders, serious mental illnesses, cocaine and opioid overdose remedies, and alcohol dependence, positioning it with one of the largest addiction drug pipelines globally. Founded in 1994 as a Reckitt Benckiser division and spun off in December 2014, Indivior PLC maintains global headquarters in North Chesterfield, Virginia, with key operations in the United States (accounting for the majority of revenue), United Kingdom, and over 30 countries; it employs approximately 1,051 people and focuses on healthcare providers, criminal justice systems, and patients via evidence-based treatments. Recent developments include the completion of its fourth $100 million share repurchase program in January 2025 with 9.4 million shares canceled; a November 2024 debt refinancing via $400 million senior secured notes ($350 million term, $50 million revolver undrawn); FDA approval of SUBLOCADE label changes in February 2025 enabling rapid initiation; appointment of Joseph Ciaffoni as CEO in February 2025 and Patrick Barry as Chief Commercial Officer in May 2025; launch of the three-phase Indivior Action Agenda in Q2 2025 emphasizing U.S. SUBLOCADE growth and organizational simplification; delisting from the London Stock Exchange in July 2025 while retaining primary Nasdaq listing; conclusion of legacy U.S. Department of Justice matters in November 2025; and raised full-year 2025 guidance following Q3 results with total net revenue reaching $302 million in Q2 driven by SUBLOCADE momentum.
Company News
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Indivior (OTCMKTS:INVVY) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Is Indivior Stock a Buy After Higher 2026 Guidance?
Bears are Losing Control Over Indivior Pharmaceuticals Inc. (INDV), Here's Why It's a 'Buy' Now
Indivior to Participate in Upcoming Investor Conferences
Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy?
Indivior Pharmaceuticals Inc. (INDV) Upgraded to Strong Buy: Here's What You Should Know
Indivior Announces $175 Million Accelerated Share Repurchase
Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript
Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat Estimates